Skip to main content
Premium Trial:

Request an Annual Quote

Genizon Raises $31M to Support Genome-Wide Association Studies for Metabolic Syndrome

NEW YORK (GenomeWeb News) - Genizon BioSciences said today that it has closed a Series E financing round worth CAD$31 million (US$30.8 million) that it will use to support genome-wide association studies for metabolic syndrome.
BTF, a venture capital fund based in the Netherlands, was the lead investor for the round.
Genizon said the new financing brings its total funding since it was founded in 1999 to more than $130 million.
The company said it will use the new funding to support genome-wide association studies in obesity, type 2 diabetes, dyslipidemia, and hypertension. The company said it will also evaluate links between metabolic syndrome, coronary heart disease, and Alzheimer's disease, and will study genes it has discovered in longevity “that appear to protect against these diseases.”

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.